ESR1 and breast cancer: Additionally, the combination of entinostat and exemestane was evaluated in several clinical trials on patients with post-menopausal ER+ breast cancer (NCT01594398, NCT02820961, NCT02115282, NCT03538171, NCT02833155, and NCT00828854).